BioWorld MedTech

April 13, 2016

Atricure probes underpenetrated AF market with latest FDA clearance

Flexibility is the key differentiator of Atricure Inc.'s newest FDA-cleared device. The company launched the Cryoform cryoablation probe in Europe last year under a CE mark and now has an FDA 510(k) clearance for the U.S. market. Read More

Forbion closes third venture fund at $208M; eyes on early stage

PAD awareness still an issue for doctors

ODAC: Rociletinib doesn't rise to the accelerated approval challenge

Singapore zeroes in on med-tech as a viable growth opportunity

Other news to note

Financings

Appointments and advancements

Daily M&A

Product Briefs

Keeping you up to date on recent developments in oncology

Today's news in brief

BioWorld

BioWorld briefs for April 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 8, 2025.

Many med-tech company supply chains protected from tariffs

BioWorld MedTech

In the wake of the pandemic, many leading med-tech companies took steps to on-shore and near-shore manufacturing, a move that could protect significant numbers of...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Impact of Trump tariffs on med tech proving difficult to anticipate

BioWorld MedTech

The Trump administration’s declaration of a new round of tariffs did not sit well with trade associations, but the impact of those tariffs may vary somewhat by...